Ketamine

Psychiatrists Call for Ketamine Insurance Coverage

Retrieved on: 
Thursday, April 20, 2023
Mental Health, Public Policy, Government, Healthcare Reform, Health, Health Insurance, Pharmaceutical, Insurance, Depression, Anxiety, Multimedia, Medicine, Incidence, Ketamine, Patient, FDA, TRD, Mental health, PTSD, Nursing, Pharmaceutical industry, Hospital

Leading psychiatrists are challenging inconsistent medical insurance coverage for ketamine, a key medication for patients with treatment-resistant depression, anxiety and other severe mental health conditions.

Key Points: 
  • Leading psychiatrists are challenging inconsistent medical insurance coverage for ketamine, a key medication for patients with treatment-resistant depression, anxiety and other severe mental health conditions.
  • And in too many cases, insurance coverage is the only barrier.”
    The blog details seven reasons why ketamine should be insured and encouraged for severely depressed and suicidal patients:
    Ketamine is in general use in the medical community in the US and internationally.
  • Ketamine has been proven safe and effective—in fact it can be life-saving—for depression and anxiety patients who have often found no relief from traditional antidepressants.
  • Oklahoma City psychiatrist Rachel Dalthorp is actively appealing to Oklahoma legislators and medical directors at major insurers to move ketamine insurance forward.

Psycheceutical Bioscience, Inc. Named a 2023 Top 10 Biotech Startup by Life Sciences Review

Retrieved on: 
Thursday, April 13, 2023
Janus, Hallucination, Paranoia, Multidisciplinary Association for Psychedelic Studies, Depression, Anxiety, Brain, Research, MAPS, Patient, OTC, Drug development, Ketamine, PTSD, Safety, Pharmaceutical industry, Q2

MIAMI, April 13, 2023 /PRNewswire/ -- Psycheceutical Bioscience, Inc ("Psycheceutical" or the "Company") (OTC: BWVI), a bioscience company dedicated to developing cutting-edge technologies for the next generation of mental health treatments, was named in Life Sciences Review's Top 10 Biotech Startups for 2023. Psycheceutical earned recognition for its significant progress in developing innovative patented delivery technologies that are intended to increase the safety and efficacy of psychedelic compounds.

Key Points: 
  • As Psycheceutical prepares to begin clinical trials for its novel NeuroDirect™ ketamine topical to treat PTSD, the company is named to Life Science Review's yearly Top Biotech Start-Up List
    MIAMI, April 13, 2023 /PRNewswire/ -- Psycheceutical Bioscience, Inc ("Psycheceutical" or the "Company") (OTC: BWVI), a bioscience company dedicated to developing cutting-edge technologies for the next generation of mental health treatments, was named in Life Sciences Review's Top 10 Biotech Startups for 2023 .
  • According to Life Sciences Review, "Psycheceutical's combination of innovative technologies and neurological experience helps to differentiate them in the bioscience market.
  • Psycheceutical achieves this with two patented technologies, the NeuroDirect™ topical delivery system and Janus particles .
  • "We are proud to receive this distinction from Life Sciences Review and are honored to join the list of so many exciting biotech startups," said Psycheceutical CEO Chad Harman.

Ketamine-assisted Wellness: The Center for New Growth Partners With Humboldt Social to Offer Psychotherapy Retreats

Retrieved on: 
Wednesday, April 12, 2023
Women, Other Science, Practice Management, Research, Managed Care, General Health, Men, Telemedicine, Virtual Medicine, Other Health, Consumer, Other Travel, Vacation, Mental Health, Parenting, Travel, LGBTQ+, Alternative Medicine, Health, Science, Other Consumer, Depression, The Center, Anxiety, Humboldt, Trauma, Multimedia, Massage, Beauty, City, Patient, Ketamine, Social, Tourism, Nursing

Humboldt Social , a California hospitality and wellness group, and The Center for New Growth , Humboldt County’s first ketamine and integrative mental health practice, announced today the launch of a new, immersive ketamine-assisted therapy retreat.

Key Points: 
  • Humboldt Social , a California hospitality and wellness group, and The Center for New Growth , Humboldt County’s first ketamine and integrative mental health practice, announced today the launch of a new, immersive ketamine-assisted therapy retreat.
  • View the full release here: https://www.businesswire.com/news/home/20230411005932/en/
    The Center for New Growth is partnering with Humboldt Social for Psychotherapy Retreats at Scotia Lodge.
  • The 2023 retreats dates are currently scheduled for June 11-14, August 6-9, November 2-5, and February 18- 21 in 2024.
  • For more information on The Center for New Growth, or to make a retreat reservation, please visit the Scotia Lodge website or The Center for New Growth website .

ESO Releases 2023 ESO EMS Index to Explore Key Trends and Measures Affecting EMS Agencies across the Country

Retrieved on: 
Tuesday, April 11, 2023
Technology, Hospitals, Health Technology, Cardiology, Software, Other Health, General Health, Pharmaceutical, Health, Data Management, Naloxone, ESO, EKG, Respiratory rate, Stroke, NSTEMI, Record, STEMI, Research, Attention, EMS, JPMorgan GBI-EM Index, Capnography, Hospital, Oxygen saturation (medicine), Patient, Emergency medical services, Ketamine, Drug, Periodic breathing, CPR, Public health surveillance, Nursing, Medical device

ESO, the leading data and software company serving emergency medical services (EMS), fire departments, hospitals, state and federal agencies, today announced the findings of its 2023 ESO EMS Index .

Key Points: 
  • ESO, the leading data and software company serving emergency medical services (EMS), fire departments, hospitals, state and federal agencies, today announced the findings of its 2023 ESO EMS Index .
  • Additionally, this year’s Index takes a deeper look at patient race/ethnicity and gender across metrics to identify inequities in care.
  • “Ketamine use in EMS has been a topic of interest in recent years due to patient safety concerns.
  • Additionally, as the Index findings indicates, there is opportunity for improvement in monitoring a patient’s EtCO2 following administration of ketamine.”
    The full 2023 ESO EMS Index can be downloaded here.

Kure Opens Dedicated Ketamine Infusion Therapy Facility in Los Angeles

Retrieved on: 
Tuesday, April 11, 2023
Alternative Medicine, Pharmaceutical, Health, Mental Health, Yoga, Emergency medicine, Anxiety, Suite, Administration, Ketamine, Gold, Patient, Accreditation, Meditation, Psychiatry, Bipolar disorder, PTSD, Safety, Nursing

Southern California-based ketamine infusion clinic Kure has officially opened its doors at 2730 Wilshire Blvd., Suite 425 in Santa Monica.

Key Points: 
  • Southern California-based ketamine infusion clinic Kure has officially opened its doors at 2730 Wilshire Blvd., Suite 425 in Santa Monica.
  • Kure helps patients in L.A. and surrounding areas live fuller lives through dedicated ketamine therapy that meets the growing demand for effective solutions to treat mental health conditions.
  • He prides himself on providing the gold standard of ketamine therapy and has successfully treated those suffering from chronic treatment-resistant depression, bipolar disorder, anxiety, PTSD, and substance use disorders for several years.
  • Kure is open by appointment Monday through Friday from 9 a.m. to 6 p.m. As a licensed medical facility, Kure meets all state and federal regulations.

Science-Forward Skincare Brand A.P. CHEM® Debuts New Age-Decelerating Products and Stigma-Breaking Social Campaign

Retrieved on: 
Tuesday, April 11, 2023
Mental Health, Millennials, Philanthropy, Alternative Medicine, Consumer, Health, Cosmetics, Generation X, Foundation, Retail, Psychedelic treatments for trauma-related disorders, GABA, Interior design, Autoimmunity, Gen, Inflammation, Hairdresser, Overalls, PTSD, CHEM, Multimedia, Classic, Veteran, Psychedelic drug, Judgement, Ketamine, Xennials, Collection, Serum, Diagnosis, Entrepreneurship, Mental health, Skin, Pharmaceutical industry

CHEM announces the launch of their newest age-decelerating skincare aimed at the Xennial and Gen X community that is both results-driven and accessibly priced.

Key Points: 
  • CHEM announces the launch of their newest age-decelerating skincare aimed at the Xennial and Gen X community that is both results-driven and accessibly priced.
  • CHEM combines the best of classic ingredients with clinically-proven Alt-Pharma™ ingredients to create a power-packed regimen.
  • “Our brand ethos is unique in its advocacy for Psychedelic Medicine because of my personal experience and connection to the cause.
  • CHEM and the “We See You” campaign, please visit www.apchembeauty.com and follow on Instagram at @apchembeauty .

Relief Mental Health expands services in Milwaukee area with transcranial magnetic stimulation for smoking addiction

Retrieved on: 
Thursday, April 6, 2023
Other Consumer, Health, Women, Pharmaceutical, Men, Mental Health, Health Technology, Other Science, Family, Consumer, Science, Neuron, Depression, Esketamine, Tobacco smoking, Tic disorder, Brainsway, TMS, Disability, Transcranial magnetic stimulation, Mental health, Brain, Tobacco, CDC, Molina Healthcare, Ketamine, FDA, Smoking, Death, Disease, Pharmaceutical industry

Relief Mental Health , an outpatient provider of transcranial magnetic stimulation (TMS), psychedelic therapy (SPRAVATO® esketamine), psychiatric medication management, and talk therapy, has added smoking addiction treatment in its West Allis location with cutting-edge BrainsWay Deep TMS technology.

Key Points: 
  • Relief Mental Health , an outpatient provider of transcranial magnetic stimulation (TMS), psychedelic therapy (SPRAVATO® esketamine), psychiatric medication management, and talk therapy, has added smoking addiction treatment in its West Allis location with cutting-edge BrainsWay Deep TMS technology.
  • It uses electromagnetic pulses to stimulate neurons in parts of the brain, reducing tobacco cravings and increasing cognitive control.
  • According to the CDC , smoking leads to disease and disability and harms nearly every organ of the body.
  • “Most adult cigarette smokers want to quit but have trouble doing so on their own,” said Susan Mueller, founder and CEO of Relief Mental Health.

Vistagen Receives New European Patent for AV-101

Retrieved on: 
Thursday, April 6, 2023
Biotechnology, Pharmaceutical, Health, Clinical Trials, Central nervous system, Depression, Anxiety, Opposition procedure before the European Patent Office, NMDAR, CNS, EPO, DSM-IV codes, Patent, Patient, Central nervous system disease, Neuropathic pain, European Patent Convention, Ketamine, Dyskinesia, Pharmaceutical industry

Vistagen (NASDAQ: VTGN) a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system (CNS) disorders, today announced that the European Patent Office (EPO) has granted the Company a patent for AV-101, its oral NMDAR (N-methyl-D-aspartate receptor) glycine site antagonist.

Key Points: 
  • Vistagen (NASDAQ: VTGN) a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system (CNS) disorders, today announced that the European Patent Office (EPO) has granted the Company a patent for AV-101, its oral NMDAR (N-methyl-D-aspartate receptor) glycine site antagonist.
  • The patent relates to the synthesis of AV-101 and certain chemical intermediaries, which synthesis yields AV-101 in commercial quantities and has the scalability for commercial manufacture.
  • The new European patent is a counterpart to previously granted U.S. patent 11,427,530 and will be in effect until at least 2039.
  • “Expanding our patent portfolio for all of our product candidates is an ongoing priority to support our global development and commercialization strategies across our pipeline,” said Shawn Singh, Chief Executive Officer of Vistagen.

Delic Holdings Corp. Signs LOI with Peter/PetraMD to Acquire Ketamine Wellness Centers and Facilitate Online Ketamine Treatments Nationwide

Retrieved on: 
Monday, April 3, 2023
Biotechnology, Alternative Medicine, Pharmaceutical, Health, Ketamine, Knowledge, Telehealth, Woman, Acquisition, Patient, KWC, Hospital

Peter/PetraMD, the largest online provider of hormone therapy for men and women in the United States, today announced the intent to acquire Ketamine Wellness Centers.

Key Points: 
  • Peter/PetraMD, the largest online provider of hormone therapy for men and women in the United States, today announced the intent to acquire Ketamine Wellness Centers.
  • If successful, the acquisition would represent an incredible on-ramp into the ketamine space for Peter/PetraMD.
  • With over 20 years of experience and nearly 100,000 patients across the United States, Ketamine Wellness Centers is the largest ketamine infusion therapy provider in the US and only a handful to accept most major insurances.
  • Peter/PetraMD has said they intend to maintain continuity of care for current patients of Ketamine Wellness Centers while also seeking to expand into the national market with the knowledge and expertise provided by leadership.

Delic Holdings Corp. signs LOI with Peter/PetraMD to acquire Ketamine Wellness Centers and facilitate online Ketamine treatments nationwide.

Retrieved on: 
Tuesday, April 4, 2023
Ketamine, Knowledge, Telehealth, Woman, Acquisition, Patient, KWC, Pharmaceutical industry

TULSA, Okla., April 4, 2023 /PRNewswire/ -- Peter/PetraMD, the largest online provider of hormone therapy for men and women in the United States, today announced the intent to acquire Ketamine Wellness Centers.

Key Points: 
  • TULSA, Okla., April 4, 2023 /PRNewswire/ -- Peter/PetraMD, the largest online provider of hormone therapy for men and women in the United States, today announced the intent to acquire Ketamine Wellness Centers.
  • If successful, the acquisition would represent an incredible on-ramp into the ketamine space for Peter/PetraMD.
  • With over 20 years of experience and nearly 100,000 patients across the United States, Ketamine Wellness Centers is the largest ketamine infusion therapy provider in the US and only a handful to accept most major insurances.
  • Peter/PetraMD has said they intend to maintain continuity of care for current patients of Ketamine Wellness Centers while also seeking to expand into the national market with the knowledge and expertise provided by leadership.